Cardiac Surgery Requiring Cardiopulmonary Bypass
16
2
3
10
Key Insights
Highlights
Success Rate
91% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
6.3%
1 terminated out of 16 trials
90.9%
+4.4% vs benchmark
13%
2 trials in Phase 3/4
20%
2 of 10 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 10 completed trials
Clinical Trials (16)
The Association Between Tau & GFAP and Postoperative Neurological Impairment in Patients Undergoing Cardiac Surgery
SIRAKI 02 Posthoc Analysis.
A Comparison of Renal vs Limb NIRS for Predicting Cardiac Surgery Associated Acute Kidney Injury
Role of Levothyroxine Supplementation in Delayed Recovery Following Cardiac Surgery
Vancomycin Concentration Analysis in Post-Cardiac Surgery Patients
Clinical Outcomes Between Pulsatile and Non-Pulsatile Flow During Cardiopulmonary Bypass
Biocompatible Versus Non-coated Extracorporeal Circuits in Cardiac Surgery
Oxygen Consumption, Hypoperfusion and Organ Injury After Cardio-pulmonary Bypass
Relation Between Insulinoresistance and Neutrophile to Lymphocyte Ratio in Cardiac Surgery.
Relationship of Point-of-care Coagulation Assays with Clinical Outcomes in Cardiac Surgery: a Retrospective Cohort Study
Comparison of the Performance and Effectiveness of Two Transfusion-Saving Devices: Cell-Saver and SAME
Multi-national Study Investigating the Effect and Safety of rFXIII on Transfusion Needs in Patients Undergoing Heart Surgery
Activated Recombinant Human Factor VII Following Cardiac Bypass Surgery for Paediatric Congenital Heart Disease
Use of Activated Recombinant Human Factor VII in Cardiac Surgery
Safety of rFXIII in Patients Following First Time Myocardial Revascularization Requiring Cardiopulmonary Bypass
Safety of Recombinant Factor XIII (rFXIII) in Healthy Japanese Volunteers